Related Experiment Video
Updated: Jun 1, 2026
07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia
Ming Jiang1, Douglas W Strand, Omar E Franco
1Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA. ming.jiang.1@vanderbilt.edu
Differentiation; Research in Biological Diversity
|June 8, 2011
Summary
Metabolic syndrome is linked to benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). PPARγ signaling may offer a molecular target for treating BPH/LUTS in patients with metabolic disease.
Area of Science:
- Urology
- Endocrinology
- Metabolic Diseases
Background:
- Metabolic syndrome is a growing epidemic with serious health consequences.
- Benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) are common in aging men.
- The connection between metabolic syndrome and BPH/LUTS requires further investigation.
Purpose of the Study:
- To explore the relationship between BPH/LUTS and systemic metabolic disease.
- To identify potential molecular targets for BPH/LUTS treatment within the context of metabolic dysfunction.
- To introduce novel research models for studying metabolic influences on prostate growth.
Main Methods:
- Review of retrospective clinical studies associating BPH/LUTS with type II diabetes, inflammation, and dyslipidemia.
- Discussion of the role of PPARγ signaling in metabolic regulation and its potential link to BPH/LUTS.
- Introduction of new cell and animal models for investigating obesity, diabetes, and inflammation effects on prostate.
Main Results:
- Retrospective studies indicate associations between BPH/LUTS and type II diabetes, inflammation, and dyslipidemia.
- PPARγ signaling is identified as a potential molecular pathway connecting metabolic disease and BPH/LUTS.
- New models are established to study the impact of metabolic factors on benign prostatic growth.
Conclusions:
- BPH/LUTS may be influenced by systemic metabolic conditions like type II diabetes, inflammation, and dyslipidemia.
- PPARγ signaling presents a promising target for therapeutic intervention in BPH/LUTS related to metabolic syndrome.
- Ongoing research using advanced models will further elucidate the consequences of metabolic diseases on prostate health.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...